



Ref. No.: EIKO/BSE/2024-25/18

Date: 13th August, 2024.

To,
Corporate Services Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
1st Floor, Dalal Street,
Fort, Mumbai - 400001.

Scrip Code: 540204

Subject: Outcome of the Board Meeting

Dear Sir/Madam,

Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), and amendments thereto, this is to inform that the Meeting of the Board of Directors of the Company held today i.e., on Tuesday, 13th August, 2024, Board, inter-alia, considered and approved the Unaudited Financial Results (Standalone & Consolidation basis) for the Quarter ended 30th June, 2024.

The Statutory Auditors have carried out a "Limited Review" of the Unaudited Financial Results for the Quarter ended 30th June 2024. Further, Pursuant to the Regulation 33 of the Listing Regulations, we are enclosing herewith a copy of the Unaudited Financial Results and Limited Review Report of the Statutory Auditors of the Company.

The said results shall be published in one English and one vernacular newspaper as required. This intimation is also available on the Company's website at www.eikolifescienceslimited.com

The Meeting was commenced at 5.15 PM and concluded at 5.45 PM.

Please take the same on your records.

For Eiko Lifesciences Limited

Chintan Doshi
Company Secretary and Compliance Officer
Membership No: A 36190



EIKO LIFESCIENCES LIMITED
(CIN: L65993MH1977PLC258134)

STATEMENT OF STANDALONE AND CONSOLIDATED PROFIT AND LOSS FOR THE QUARTER ENDED 30-06-2024

(₹ in Lakhs)

Sr. No.	Particulars	Standalone				Consolidated
		Quarter ended		Year ended		Quarter Ended
		30.06.2024	31.03.2024	30.06.2023	31.03.2024	30.06.2024
		(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)
1	Revenue from operations	1,075.04	839.79	650.78	2,792.93	1,075.04
	Other income	26.23	10.63	2.72	17.61	26.23
2	Total revenue	1,101.26	850.42	653.50	2,810.54	1,101.26
3	Expenses					
	Cost of material consumed	992.16	840.28	603.55	2,720.48	992.16
	Changes in inventories of finished stock and work-in-progress	(0.16)	(65.28)	(0.44)	(179.07)	(0.16)
	Employee benefits expense	13.05	5.30	5.34	22.07	13.05
	Depreciation and amortization expense	16.53	18.06	16.05	66.25	16.53
	Finance Cost	2.88	2.24	3.37	14.21	2.88
	Other expenses	30.67	7.54	14.78	68.17	30.67
4	Total expenses	1,055.14	808.14	642.63	2,712.12	1,055.14
5	Profit/(Loss) from ordinary activities before tax	46.13	42.29	10.87	98.42	46.13
6	Tax expense:					
	(1) Current tax	8.57	9.82	-	9.82	8.57
	(2) Earlier year's Tax	-	0.03	-	0.03	-
	(4) Deferred tax	2.88	1.14	2.86	13.42	2.88
7	Profit/(Loss) from ordinary activities after tax	34.68	31.29	8.00	75.15	34.68
	Share of Profit from Associates (net of tax)	-	-	-	-	2.45
8	Net profit after taxes and share of profit of Associates	-	-	-	-	37.13
9	Other Comprehensive Income (OCI)					
	Item that will not be reclassified to profit or loss					
	Gain/(Loss) on recognised on fair valuation of Financial Assets	-	-	-	-	-
	Income tax relating to these items	-	-	-	-	-
10	Total Other Comprehensive Income (OCI)	-	-	-	-	-
11	Profit/ (Loss) for the Period	34.68	31.29	8.00	75.15	37.13
	Paid up Equity Share Capital (Face Value of Rs. 10 each)	1,287.28	1,287.28	831.63	1,287.28	1,287.28
12	Earnings Per Share (EPS) (Not annualised)					
	(1) Basic	0.27	0.28	0.10	0.73	0.29
	(2) Diluted	0.27	0.28	0.10	0.73	0.29




Notes:

1. The above unaudited Standalone and Consolidated financial results for the quarter ended 30th June 2024 were reviewed by the audit committee of the board on 13th August 2024 and thereafter approved by the board of directors of the company at their meeting held on 13th August 2024.
2. The above unaudited Standalone and Consolidated financial results for the quarter ended 30th June 2024 were reviewed by the statutory auditor of the company under regulation 33 of Securities & Exchange board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended. An unqualified limited review report was issued by them thereon.
3. The group has a single business segment, namely "Speciality & Fine Chemicals" therefore in the context of Ind As 108, disclosure of segment information is not applicable.
4. The Right Issue Committee of the Board of Directors of the Company at its meeting held on Thursday, 14-12-2023, approved the making of First and Final Call of Rs. 31.50/- (Rupees Thirty-One and Fifty Paise Only) on 55,44,178 Partly Paid-up Equity Shares. The Company fixed Friday, 22-12-2023 as the Record Date for the purpose of determining the holders of Partly Paid-up Equity Shares to whom the call notice with the dispatched for payment of the call. The listing approval for fully paid-up shares which were converted by payment of first and final call was received on 02-02-2024. The Right Issue Committee of the Board of Directors of the Company at its meeting held on 08-02-2024, decided to give another opportunity to the shareholders holding Rights Equity Shares, who did not pay the First and Final Call money earlier. Accordingly, listing approval of fully paid-up shares converted pursuant to payment of reminder call was received on 28-03-2024. Pursuant to IND AS 33, basic and diluted earnings per share for the previous periods have been restated for the bonus element in respect of right issue made during the quarter and year ended 31-03-2024.
5. During the quarter, the company successfully acquired a 25.01% equity stake in Reflux Pharmaceuticals Private Limited ("RPPL"), thereby making it an associate company of Eiko LifeSciences Limited. As a result, consolidated financial results have been prepared and presented for the current quarter. Since this is the first period in which consolidated financial statements are being reported, comparative figures for prior periods are not available.
6. The figures for the quarter ended March 31, 2024, as reported in these financial results are the balancing figures between the audited figures in respect of the full previous financial year and the published year-to-date figures up to the end of the third quarter of the previous financial year, which were subjected to limited review
7. The figures for the corresponding previous quarter/ year have been regrouped/reclassified wherever necessary, to make them comparable.

For Eiko LifeSciences Limited

Laxmikant Kabra
Chairman
DIN: 00061346



Date: 13th August 2024

Place: Thane

Independent Auditor's Review on the Unaudited Standalone Quarterly Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To the Board of Directors
Eiko Lifesciences Limited

1. We have reviewed the accompanying statement of Unaudited Standalone Financial Results of **Eiko Lifesciences Limited** (the "Company") for the quarter ended June 30, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial result prepared in accordance with applicable Principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement

For Thanawala & Company
Chartered Accountants
Firm Reg. No.: 110948W



CA Vijay Thanawala
Proprietor
Membership No.: 015632



Place: Mumbai
Date: 13th August 2024

UDIN: 24015632BKGWWT8221

Independent Auditor's Review on the Unaudited Consolidated Quarterly Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**To the Board of Directors
Eiko LifeSciences Limited**

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of **Eiko LifeSciences Limited** (the "Parent") and its Associate (the parent and its associate referred to as Group) for the quarter ended June 30, 2024 (the "Statement") attached herewith, being submitted by the parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parents's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. The statement includes the results of following entity:

Parent	
1	Eiko LifeSciences Limited
Associate	
2	Reflux Pharmaceuticals Private Limited

4. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial result prepared in accordance with applicable Principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement
6. We did not review the interim financial results of associate included in the Statement whose interim financial information reflects total revenues of Rs. 633.35 lakhs and net profit of Rs. 13.10 lakhs for the quarter ended 30th June 2024 as considered in the Statement. These interim financial results have been reviewed by other auditors and our conclusion on





the Statement, in so far as it relates to the amounts and disclosures included in respect of associate is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.

For Thanawala & Company

Chartered Accountants

Firm Reg. No.: 110948W

CA Vijay Thanawala

Proprietor

Membership No.: 015632



Place: Mumbai

Date: 13th August 2024

UDIN: 24015632BKGWWU4298